Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Technique Selectively Represses Immune System

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Technique might be used to treat multiple sclerosis and other autoimmune disorders.

Researchers devised a way to successfully treat symptoms resembling multiple sclerosis in a mouse model.

With further development, the technique might be used to treat multiple sclerosis and other autoimmune disorders.

Multiple sclerosis is an autoimmune disease-a type of disease in which the immune system mistakenly attacks the body’s own tissues.

In multiple sclerosis, immune system T cells attack myelin, the insulating material that encases nerve fibers.

Resulting nerve damage in the brain and spinal cord can cause muscle weakness, loss of vision, numbness or tingling, and difficulty with coordination and balance. It can also lead to paralysis.

Current treatments for autoimmune disorders involve the use of immunosuppressant drugs. These work by tamping down immune system activity.

However, they can also leave patients susceptible to infections and increase their risk of cancer.

Drs. Stephen Miller and Lonnie Shea at Northwestern University teamed up with researchers at the University of Sydney and the Myelin Repair Foundation in California to come up with a more targeted approach.

They aimed to repress only the part of the immune system that causes autoimmune disorders while leaving the rest of the system intact.

Their new approach takes advantage of a natural safeguard used by the body to deactivate T cells that have the potential to attack the body’s healthy tissues.

Apoptotic, or dying, cells release chemicals that attract immune system cells called macrophages.

Macrophages gobble up the dying cells and deliver them to the spleen, where they present self-antigens-tiny portions of proteins from the dying cells-to a pool of T cells.

To ensure that T cells don’t attack the body’s own tissues, the macrophages initiate the repression of any T cells that bind to the self-antigens.

In previous work, Miller’s group was able to couple specific self-antigens such as myelin to apoptotic cells to tap into this natural mechanism and suppress T cells that would normally attack the body’s own tissue. However, using apoptotic cells as a vehicle proved to be a costly, difficult and time-consuming procedure.

In the new study, the team linked myelin antigens to microscopic, biodegradable particles in the hope that these would be similarly taken up by circulating macrophages.

Their work was partly supported by NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB) and National Institute of Neurological Disorders and Stroke (NINDS). The study appeared online on November 18, 2012, in Nature Biotechnology.

The myelin-bound particles proved to be just as good as apoptotic cells, if not better, at inducing T-cell tolerance in a mouse model of multiple sclerosis. The particles both prevented symptoms and slowed their progression when injected at first detection of disease symptoms.

The team is hoping to begin phase I clinical trials in the near future. The material that makes up the particles has already been approved by the U.S. Food and Drug Administration for other uses.

The researchers are also exploring the approach to treat other autoimmune diseases such as type 1 diabetes and food allergies.

“I think we've come up with a very potent way to induce tolerance that can be easily translated into clinical practice,” Miller says. “We’re doing everything we can now to take this forward.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Thursday, October 20, 2016
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Wednesday, October 05, 2016
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Saturday, October 01, 2016
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
Friday, August 26, 2016
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Tuesday, August 23, 2016
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Friday, August 12, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Wednesday, July 27, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Wednesday, May 18, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
Contribution Increases by Tenfold The Mouse Mutation Resources of One Type Available
The repository provides academic researchers with unique genetic models that are unavailable commercially.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos